SciELO - Scientific Electronic Library Online

 
vol.53 issue3Effect of propofol in combination with ephedrine upon the onset time of cisatracurium author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Revista da Associação Médica Brasileira

Print version ISSN 0104-4230

Abstract

FORTI, Neusa  and  DIAMENT, Jayme. Apolipoprotein B and A-I: cardiovascular risk factor?. Rev. Assoc. Med. Bras. [online]. 2007, vol.53, n.3, pp. 276-282. ISSN 0104-4230.  http://dx.doi.org/10.1590/S0104-42302007000300029.

Apolipoprotein (apo) B is present in atherogenic lipoproteins (remnant Qm and VLDL, LDL and Lp (a)) and apo A is present in non-atherogenic lipoprotein (HDL). Measurement of the apos is automated, standardized, with a small variation of coefficient and does not require fasting blood samples. The authors reviewed clinical, epidemiological and therapeutic trials on hyperlipidemia with apo B and A-I evaluation. These works showed the importance of apo B and A-I as cardiovascular risk factors. Experts recommended apo B / apo A-I ratio as an alternative to TC / HDL-c ratio for risk estimate. Future positioning from the Guidelines is expected to include apos in individual risk prediction and as a therapeutic target. The authors suggest that, in clinical practice, measurement of apo B is necessary for coronary heart disease patients with desirable LDLc levels or when this assessment is not possible and the measurement of apo A-I if HDL-c values are very low.

Keywords : Apolipoprotein; Risk factor; Cardiovascular disease.

        · abstract in Portuguese     · text in Portuguese     · pdf in Portuguese